MICROLIGHT3D | Linksium
Back to portfolio

MICROLIGHT3D

Incorporated startups

Laser printer and 3D software adapted to cellular biology

profilePhoto   Philippe Mattia
Linksium Contact Philippe Mattia +33 (0)4 57 13 81 65 philippe.mattia@linksium.fr
profilePhoto   Denis Barbier, CEO
MICROLIGHT3D Denis Barbier, CEO +33 (0)4 76 54 95 16 denis.barbier@microlight.fr
150014 MICROLIGHT3 D e1531913391777

Benefits

  • Quick and precise 3D microprinting
  • Made-to-measure manufacture of micro-objects
  • Capacity to form biocompatible materials for regenerative medicine

Key words

  • Bioprinting
  • 3D microprinting
  • Micro-skeletons
  • Biocompatible materials

Intellectual Property

  • 1 patent
  • 1 software
  • 3 knowhow

Partnerships & Rewards

  • 2018 French Deeptech Innovation Competition Winner

Laboratory

  • LIPHY

Institutions

  • CNRS
  • UGA

Linksium Continuum

  • Maturation
  • Incubation

Results

  • Incorporated startups

Context

3D printing is either precise and slow, or fast and low-resolution. This quick and precise technology meets the needs of the markets for the production of micro-objects for research ($40M), the production of artificial implants or tissues ($965M) and high-resolution surface structuring.

Technology

3D microprinting makes it possible to reproduce the complexity of living organisms with biocompatible materials in order to obtain objects of several cm² in just a few minutes. All of the resins will be usable, whatever their spectral absorption range from 3 possible laser sources.

Advantages

Previously built by hand, the micro-skeletons will be created with a resolution unequalled up to now (0.1 microns, a fraction of the size of a cell) in very short periods of time (write speed of 10 mm/s) and at a price over 2 times lower than the competition.

State of progress

Company created in December 2016, first product placed on the market in 2017. Support from: UGA, CNRS, G-INP, INRiA, SATT-Linksium, Grenoble Alpes Métropole.

Applications

The users (cellular biology laboratories, biomedical implant manufacturers, molecule screening specialists) will be able to cultivate cells for complex tissues for the purposes of regenerative medicine and pharmacology and cosmetics testing.